Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.64 |
| ▸ | KDR | P35968 | 12/20 | 0.64 |
| ▸ | FLT1 | P17948 | 5/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.64 |
| ▸ | FLT4 | P35916 | 3/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.62 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 4/20 | 0.62 |
| ▸ | KIF5B | P33176 | 3/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139115 | 0.90 | KDR (0.66) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL159652 | 0.89 | KDR (0.80) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL7962820 | 0.88 | KDR (0.73) | EGFRKDRFLT1FGFR1FLT4 | |
| Hydrochloric Acid SCHEMBL1468204 | 0.88 | KDR (0.78) | EGFRKDRFLT1FGFR1FLT4 | |
| Hydrochloric Acid SCHEMBL7215101 | 0.87 | KDR (0.72) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL30891782 | 0.82 | EGFR (0.83) | EGFRKDRFLT1FGFR1RET | |
| SCHEMBL22367364 | 0.82 | EGFR (0.81) | EGFRKDRFLT1FGFR1RET | |
| Hydrochloric Acid SCHEMBL1782686 | 0.82 | KDR (0.68) | EGFRKDRFLT1FGFR1FLT4 | |
| SCHEMBL8933781 | 0.81 | EGFR (0.68) | EGFRKDRFLT1FLT4RET | |
| SCHEMBL4421590 | 0.80 | TRPA1 (0.61) | EGFRKDRFLT1FLT4RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2011-03-17 | — | — | US | disclosed |
| EP-1676845-B1 | New quinazoline derivatives | ASTRAZENECA AB (SE) | 2008-06-11 | — | — | EP | disclosed |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB | 2007-11-15 | — | — | US | disclosed |
| US-7173038-B1 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| EP-1676845-A1 | New quinazoline derivatives | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1244647-B1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 199/4885KDR 3/4885FLT1 2/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 207/4885KDR 3/4885FLT1 1/4885 |
| US-20110065736-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885FLT1 1/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 179/4885KDR 3/4885FLT1 1/4885 |
| US-20070265286-A1 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | EGFR 183/4885KDR 3/4885FLT1 1/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FLT1 1/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | EGFR 120/4885KDR 3/4885FLT1 2/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 181/4885KDR 3/4885FLT1 1/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | EGFR 179/4885KDR 3/4885FLT1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.